Repligen (NASDAQ:RGEN) Upgraded at Hsbc Global Res

Key Points

• Repligen has been upgraded to a "strong-buy" rating by Hsbc Global Research, signaling positive sentiment from analysts.
• Despite missing EPS estimates by $0.03, Repligen reported a revenue increase of 14.8% year-over-year for the last quarter, totaling $182.37 million.
• Currently, the stock has an average target price of $168.08 and a majority rating of "Moderate Buy" from analysts.

Repligen (NASDAQ:RGEN - Get Free Report) was upgraded by equities research analysts at Hsbc Global Res to a "strong-buy" rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other analysts also recently issued reports on RGEN. Wells Fargo & Company cut their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th. HC Wainwright reissued a "buy" rating and issued a $180.00 price target on shares of Repligen in a report on Wednesday, September 3rd. Barclays raised their price target on Repligen from $150.00 to $160.00 and gave the stock an "overweight" rating in a report on Thursday. Evercore ISI raised Repligen from an "in-line" rating to an "outperform" rating and raised their price target for the stock from $130.00 to $155.00 in a report on Monday, September 22nd. Finally, Jefferies Financial Group cut their price target on Repligen from $145.00 to $135.00 and set a "hold" rating on the stock in a report on Friday, September 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $168.08.

Repligen Price Performance

Shares of RGEN opened at $145.23 on Wednesday. The firm has a market cap of $8.17 billion, a price-to-earnings ratio of -580.90, a PEG ratio of 2.69 and a beta of 1.08. The stock has a 50 day moving average of $121.84 and a 200-day moving average of $125.49. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. Repligen has a 52 week low of $102.96 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.Repligen's revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, analysts forecast that Repligen will post 1.72 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, Director Martin D. Madaus bought 1,800 shares of the business's stock in a transaction on Friday, August 8th. The shares were purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the purchase, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 1.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Repligen

Hedge funds have recently modified their holdings of the stock. KBC Group NV grew its stake in shares of Repligen by 14.9% in the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock valued at $324,000 after purchasing an additional 329 shares during the period. Harvest Fund Management Co. Ltd acquired a new position in shares of Repligen in the 1st quarter worth approximately $132,000. XTX Topco Ltd boosted its holdings in shares of Repligen by 34.2% in the 1st quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company's stock worth $1,646,000 after acquiring an additional 3,295 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Repligen by 40.1% in the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 274 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd boosted its holdings in shares of Repligen by 233.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company's stock worth $1,172,000 after acquiring an additional 6,448 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.